The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein
Open accessAbstract
Bacterial class 2 CRISPR-Cas systems utilize a single RNA-guided protein effector to mitigate viral infection. We aggregated genomic data from multiple sources and constructed an expanded database of predicted class 2 CRISPR-Cas systems. A search for novel RNA targeting systems identified subtype VI-D, encoding dual HEPN-domain containing Cas13d effectors and putative WYL-domain containing accessory proteins (WYL1 and WYL-b1–5). The median size of Cas13d proteins is 190 to 300 amino acids smaller than that of Cas13a-c. Despite their small size, Cas13d orthologs from Eubacterium siraeum (Es) and Ruminococcus sp. (Rsp) are active in both CRISPR RNA processing and target as well as collateral RNA cleavage, with no target-flanking sequence requirements. The RspWYL1 protein stimulates RNA cleavage by both EsCas13d and RspCas13d, demonstrating a common regulatory mechanism for divergent Cas13d orthologs. The small size, minimal targeting constraints, and modular regulation of Cas13d effectors further expands the CRISPR toolkit for RNA-manipulation and detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
MUSCLE: multiple sequence alignment with high accuracy and high throughput
Edgar, R. C. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh340 · Cited by 44,662
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
Prodigal: prokaryotic gene recognition and translation initiation site identification
Hyatt, D., Chen, G.-L., LoCascio, P. F., Land, M. L., Larimer, F. W., & Hauser, L. J. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-119 · Cited by 12,587
WebLogo: A Sequence Logo Generator: Figure 1
Crooks, G. E., Hon, G., Chandonia, J.-M., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,386
Cited by
Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants
Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., Charpentier, E., Cheng, D., Haft, D. H., Horvath, P., et al. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0299-x · Cited by 2,445
Self-citationSHERLOCK: nucleic acid detection with CRISPR nucleases
Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2019) · Nature Protocols · doi:10.1038/s41596-019-0210-2 · Cited by 1,631
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy
Fozouni, P., Son, S., Díaz de León Derby, M., Knott, G. J., Gray, C. N., D’Ambrosio, M. V., Zhao, C., Switz, N. A., Kumar, G. R., Stephens, S. I., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.001 · Cited by 1,047
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
Functionally diverse type V CRISPR-Cas systems
Yan, W. X., Hunnewell, P., Alfonse, L. E., Carte, J. M., Keston-Smith, E., Sothiselvam, S., Garrity, A. J., Chong, S., Makarova, K. S., Koonin, E. V., et al. (2019) · Science · doi:10.1126/science.aav7271 · Cited by 518
Self-citationClades of huge phages from across Earth’s ecosystems
Al-Shayeb, B., Sachdeva, R., Chen, L.-X., Ward, F., Munk, P., Devoto, A., Castelle, C. J., Olm, M. R., Bouma-Gregson, K., Amano, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2007-4 · Cited by 504
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Abbott, T. R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S., Heaton, N. S., Debs, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 498
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
Massively parallel Cas13 screens reveal principles for guide RNA design
Wessels, H.-H., Méndez-Mancilla, A., Guo, X., Legut, M., Daniloski, Z., & Sanjana, N. E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0456-9 · Cited by 418
Screening for functional circular RNAs using the CRISPR–Cas13 system
Li, S., Li, X., Xue, W., Zhang, L., Yang, L.-Z., Cao, S.-M., Lei, Y.-N., Liu, C.-X., Guo, S.-K., Shan, L., et al. (2021) · Nature Methods · doi:10.1038/s41592-020-01011-4 · Cited by 356
Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13 Systems
Yang, L.-Z., Wang, Y., Li, S.-Q., Yao, R.-W., Luan, P.-F., Wu, H., Carmichael, G. G., & Chen, L.-L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.10.024 · Cited by 353
Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR–Cas Systems
O'Connell, M. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.029 · Cited by 346
CRISPRCasTyper: Automated Identification, Annotation, and Classification of CRISPR-Cas Loci
Russel, J., Pinilla-Redondo, R., Mayo-Muñoz, D., Shah, S. A., & Sørensen, S. J. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0059 · Cited by 307
Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d
Zhang, C., Konermann, S., Brideau, N. J., Lotfy, P., Wu, X., Novick, S. J., Strutzenberg, T., Griffin, P. R., Hsu, P. D., & Lyumkis, D. (2018) · Cell · doi:10.1016/j.cell.2018.09.001 · Cited by 276
Programmable RNA targeting with the single-protein CRISPR effector Cas7-11
Özcan, A., Krajeski, R., Ioannidi, E., Lee, B., Gardner, A., Makarova, K. S., Koonin, E. V., Abudayyeh, O. O., & Gootenberg, J. S. (2021) · Nature · doi:10.1038/s41586-021-03886-5 · Cited by 263
Self-citationCas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage
Meeske, A. J., Nakandakari-Higa, S., & Marraffini, L. A. (2019) · Nature · doi:10.1038/s41586-019-1257-5 · Cited by 291
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions
Nussbacher, J. K., Tabet, R., Yeo, G. W., & Lagier-Tourenne, C. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.014 · Cited by 272
Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?
Makarova, K. S., Wolf, Y. I., & Koonin, E. V. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0033 · Cited by 270
Self-citationShmakov, S. A., Makarova, K. S., Wolf, Y. I., Severinov, K. V., & Koonin, E. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803440115 · Cited by 169
Self-citationCRISPR-Based Technologies: Impact of RNA-Targeting Systems
Terns, M. P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.018 · Cited by 168
CRISPR-based functional genomics for neurological disease
Kampmann, M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0373-z · Cited by 163
Advances in CRISPR-Cas systems for RNA targeting, tracking and editing
Wang, F., Wang, L., Zou, X., Duan, S., Li, Z., Deng, Z., Luo, J., Lee, S. Y., & Chen, S. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.03.016 · Cited by 128
RNA-Targeting CRISPR-Cas systems and their applications
Burmistrz, M., Krakowski, K., & Krawczyk-Balska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031122 · Cited by 125
Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens
Guo, X., Rahman, J. A., Wessels, H.-H., Méndez-Mancilla, A., Haro, D., Chen, X., & Sanjana, N. E. (2021) · Cell Genomics · doi:10.1016/j.xgen.2021.100001 · Cited by 79
Kelley, C. P., Haerle, M. C., & Wang, E. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111226 · Cited by 61
Csx28 is a membrane pore that enhances CRISPR-Cas13b–dependent antiphage defense
VanderWal, A. R., Park, J.-U., Polevoda, B., Nicosia, J. K., Molina Vargas, A. M., Kellogg, E. H., & O’Connell, M. R. (2023) · Science · doi:10.1126/science.abm1184 · Cited by 55
The double life of CRISPR–Cas13
Bot, J. F., van der Oost, J., & Geijsen, N. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102789 · Cited by 50
Shen, Q., Ruan, H., Zhang, H., Wu, T., Zhu, K., Han, W., Dong, R., Ming, T., Qi, H., & Zhang, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1375120 · Cited by 38
Self-citationStructural basis for the activation of a compact CRISPR-Cas13 nuclease
Deng, X., Osikpa, E., Yang, J., Oladeji, S. J., Smith, J., Gao, X., & Gao, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41501-5 · Cited by 35
Intrinsic targeting of host RNA by Cas13 constrains its utility
Li, Z., Li, Z., Cheng, X., Wang, S., Wang, X., Ma, S., Lu, Z., Zhang, H., Zhao, W., Chen, Z., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01109-y · Cited by 31
Self-citationSharma, K. K., Palakolanu, S. R., Bhattacharya, J., Shankhapal, A. R., & Bhatnagar-Mathur, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999207 · Cited by 24
Discovering CRISPR-Cas system with self-processing pre-crRNA capability by foundation models
Li, W., Jiang, X., Wang, W., Hou, L., Cai, R., Li, Y., Gu, Q., Chen, Q., Ma, P., Tang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54365-0 · Cited by 21
Collateral cleavage of 28s rRNA by RfxCas13d causes death of mice
Li, Y., Xu, J., Guo, X., Li, Z., Cao, L., Liu, S., Guo, Y., Wang, G., Luo, Y., Zhang, Z., et al. (2022) · doi:10.1101/2022.01.17.476700 · Cited by 12
Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting
Brogan, D. J., Lin, C. P., Benetta, E. D., Wang, T., Chen, F., Li, H., Lin, C., Komives, E. A., & Akbari, O. S. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169566 · Cited by 4
Metadata
- Authors
- Yan, W. X., Chong, S., Zhang, H., Makarova, K. S., Koonin, E. V., Cheng, D. R., & Scott, D. A.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 70
- Issue
- 2
- Pages
- 327-339.e5
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2793349369
- Cited by
- 462
- References
- 53
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.